https://vettapharma.com/pharmaceutical-news/fda-accepts-takedas-entyvio-sbla-for-pediatric-ibd/ 2026-06-10T09:54:08Z VETTAPHARMA en FDA Accepts Takeda's ENTYVIO sBLA for Pediatric IBD 2026-06-10T08:00:00Z Blog https://vettapharma.com/pharmaceutical-news/sanofi-stops-phase-3-riliprubart-study-in-refractory-chronic-inflammatory-demyelinating-polyneuropathy/ 2026-06-10T09:55:27Z VETTAPHARMA en Sanofi Stops Phase 3 Riliprubart Study in Refractory chronic inflammatory demyelinating polyneuropathy 2026-06-10T08:00:00Z Blog https://vettapharma.com/pharmaceutical-news/fda-approves-lillys-ebglyss-lebrikizumab-for-every-8-week-dosing/ 2026-06-10T09:56:00Z VETTAPHARMA en FDA Approves Lilly's EBGLYSS (Lebrikizumab) for Every-8-Week Dosing 2026-06-10T08:00:00Z Blog https://vettapharma.com/pharmaceutical-news/fda-approves-europes-bemotrizinol-for-u-s-sunscreens/ 2026-06-10T09:56:41Z VETTAPHARMA en FDA Approves Europe's Bemotrizinol for U.S. Sunscreens 2026-06-10T08:00:00Z Blog